Abstract: The present invention provides a novel gene encoding a protein having an excellent catalyst ability for producing (S)-N-substituted cyclic imino acid represented by the general formula (2) (=the (S)-cyclic imino acid (2)):
and to provide a novel method for producing the (S)-cyclic imino acid (2) by an asymmetric hydrolization of the N-substituted cyclic imino acid ester represented by the general formula (1):
in a manner of gene engineering technology utilizing the novel gene provided.
Abstract: Disclosed is a nucleic acid molecule from nematodes encoding for phosphoglycerate mutase (PGM) polypeptides. The PGM-like polypeptide sequence is also provided, as are vectors, host cells, and recombinant methods for production of PGM-like nucleotides and polypeptides. The invention further relates to screening methods for identifying inhibitors and/or activators, as well as methods for antibody production. Such inhibitors are useful for control nematode infection.
Type:
Grant
Filed:
February 26, 2002
Date of Patent:
November 16, 2004
Assignee:
Divergence, Inc.
Inventors:
Andrew P. Kloek, Deryck Jeremy Williams, Brandy Salmon, John D. Bradley
Abstract: The present invention provides a novel gene encoding a protein having an excellent catalyst ability for producing (S)-N-substituted cyclic imino acid represented by the general formula (2) (=the (S)-cyclic imino acid (2)):
and to provide a novel method for producing the (S)-cyclic imino acid (2) by an asymmetric hydrolization of the N-substituted cyclic imino acid ester represented by the general formula (1):
in a manner of gene engineering technology utilizing the novel gene provided.
Abstract: The present invention relates to the use of bromelaine proteases for inhibiting blood coagulation, especially for stimulating the production of plasmin, for inhibiting the production of fibrin and for inhibiting the adhesion of human thrombocytes on endothelilum cells. Especially the basic proteases isolable from raw bromelaine have proved to be particularly suitable proteases.
Type:
Grant
Filed:
July 25, 2001
Date of Patent:
October 12, 2004
Assignee:
Ursapharm Arzneimittel GmbH
Inventors:
Rainer Maurer, Klaus Eckert, Edyta Grabowska, Klaus Eschmann
Abstract: An anti-tumor pharmaceutical composition comprises the conjugation of Canavalia ensiformis-extracted protein with metal ions to form a metalloprotein complex for inhibiting the growth of tumor with enhanced activity and stability, but without toxicity.
Abstract: The present invention provides compounds which inhibit serine protease activity of matriptase or MTSP1. Also provided are pharmaceutical compositions comprising those compounds and methods of using the compounds and pharmaceutical compositions to treat conditions ameliorated by inhibition of matriptase or MTSP1. The invention provides recombinant serine protease domains and methods of using peptides comprising a recombinant serine protease domain to screen for compounds that inhibit serine protease activity of matriptase or MTSP1.
Type:
Grant
Filed:
September 8, 2000
Date of Patent:
September 28, 2004
Assignee:
Dendreon San Diego LLC
Inventors:
Edwin L. Madison, Joseph Edward Semple, Gary Samuel Coombs, John Eugene Reiner, Edgar O. Ong, Gian Luca Araldi
Abstract: Disclose herein is a novel recombinant mutant protein of human Group IIA phospholipase A2 (PLA2) which has enhanced antibacterial activity when compared to the wild-type human Group IIA PLA2, pharmaceutical formulations comprising the protein and methods of use thereof. Additionally, the formulations may comprise other bioactive compounds, such as, e.g., conventional antibiotics, that act additively or synergistically with Group IIA PLA2 in order to promote bacterial killing.
Type:
Grant
Filed:
September 25, 2002
Date of Patent:
July 27, 2004
Assignee:
New York University
Inventors:
Jerrold Weiss, Peter Elsbach, Ning-Sheng Liang
Abstract: The present invention provides an isolated polynucleotide containing a polynucleotide sequence selected from the group
a) polynucleotide which is at least 70% identical to a polynucleotide which codes for a polypeptide containing the amino acid sequence of SEQ ID no. 2,
b) polynucleotide which codes for a polypeptide which contains an amino acid sequence which is at least 70% identical to the amino acid sequence of SEQ ID no. 2,
c) polynucleotide which is complementary to the polynucleotides of a) or b), and
d) polynucleotide containing at least 15 successive nucleotides of the polynucleotide sequence of a), b) or c),
and a process for the fermentative production of L-amino acids with enhancement of the glbO gene which codes for the haemoglobin-like protein and the use of the above polynucleotides as a primer or hybridization probe.
Type:
Grant
Filed:
May 7, 2002
Date of Patent:
July 6, 2004
Assignee:
Degussa-AG
Inventors:
Bettina Mockel, Achim Marx, Walter Pfefferle
Abstract: The invention provides isolated nucleic acids molecules, designated 46798 nucleic acid molecules, which encode a novel matrix metalloproteinase. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 46798 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 46798 gene has been introduced or disrupted. The invention still further provides isolated 46798 proteins, fusion proteins, antigenic peptides and anti-46798 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
Abstract: The present invention is directed to a recombinant enzymes having alcohol and aldehyde dehydrogenase activity which comprises one or mom recombinant polypeptides selected from the group consisting of polypeptides which are identified by SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8 and chimeric recombinant polypeptides that are a chimeric combination of at least two of the following amino acid sequences identified by SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8 and functional derivatives of the polypeptides identified above which contain addition, insertion, deletion and/or substitution of one or more amino acid residues, wherein said enzymatic polypeptides have said alcohol and aldehyde dehydrogenase activity. DNA molecules encoding the recombinant polypeptides, vectors comprising such DNA molecules, host cells transformed by such vectors and processes for the production of such recombinant enzymes are provided.
Abstract: The present invention relates an isolated human Site-1 Protease promoter region. The invention also relates to screening methods for agents decreasing the expression of Site-1 protease and thereby being potentially useful for the treatment of medical conditions related to obesity and/or diabetes.
Type:
Grant
Filed:
June 26, 2001
Date of Patent:
April 20, 2004
Assignee:
Biovitrum AB
Inventors:
Lars Abrahmsén, Jonas Ekblom, Margareta Forsgren, Jan Hörling, Per Johansson
Abstract: The present invention provides polypeptides having pyrimidine glycosylase activity, preferably, pyrimidine glycosylase/AP lyase activity. The polypeptides include a targeting sequence, preferably an exogenous target sequence. The invention includes polynucleotides that include a coding sequence encoding the polypeptides of the present invention. Also provided by the invention are methods of using the polypeptides.
Type:
Grant
Filed:
May 23, 2001
Date of Patent:
April 20, 2004
Assignee:
Board of Regents, The University of Texas System
Inventors:
R. Stephen Lloyd, Amanda K. McCullough, Khoa Nguyen
Abstract: This invention relates to an isolated nucleic acid fragment encoding a sulfate assimilation protein. The invention also relates to the construction of a chimeric gene encoding all or a portion of the sulfate assimilation protein in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the sulfate assimilation protein in a transformed host cell.
Abstract: An artificial mammalian chromosome, more specifically, a clone containing a mammalian centromere sequence and a DNA replication origin with mammalian telomere sequences added to both ends of the clone, is provided by preparing a CEPH artificial yeast chromosome library containing a human genome, identifying clones having a repetitive human alphoid sequence from this library, and further preparing a yeast strain in which mammalian telomere sequences are added to the ends of its chromosome.
Abstract: A gene that encodes an inhibitor of CDK4 has been discovered and its genomic nucleotide sequence has been identified. Susceptibility to certain cancers has been shown to be causatively related to the deletion of, or polymorphisms in, the CDK4I gene. The invention is therefore directed to the gene (CDK4I), the inhibitor protein, as well as therapeutic and diagnostic methods which utilize both the CDK4I gene and the CDK4I protein.
Type:
Grant
Filed:
August 26, 1997
Date of Patent:
February 10, 2004
Assignee:
The Regents of the University of California
Abstract: Aggrecanase proteins and the nucleotides sequences encoding them as well as processes for producing them are disclosed. Methods for developing inhibitors of the aggrecanase enzymes and antibodies to the enzymes for treatment of conditions characterized by the degradation of aggrecan are also disclosed.
Type:
Grant
Filed:
October 18, 2001
Date of Patent:
February 10, 2004
Assignee:
Genetics Institute, LLC
Inventors:
Lisa A. Racie, Natalie C. Twine, Michael J. Agostino, Neil Wolfman, Elisabeth A. Morris
Abstract: The production of thermostable xylanses having bacterial origin is described. These compositions are useful for modifying plant biomass and for enzyme-aided bleaching of wood pulp.
Type:
Grant
Filed:
January 22, 1999
Date of Patent:
December 23, 2003
Assignee:
Röhm Enzyme Finland Oy
Inventors:
Arja Mäntylä, Marja Paloheimo, Raija Lantto, Richard Fagerström, Tarja Lahtinen, Pirkko Suominen, Jari Vehmaanperä
Abstract: The present invention provides new recombinantly produced vanadium haloperoxidases. The enzymes are useful in a number of industrial applications.
Type:
Grant
Filed:
June 19, 2000
Date of Patent:
December 2, 2003
Assignee:
The Regents of the University of California
Abstract: Human and rat cAMP phosphodiesterase isoforms (denoted PDE4Ds), as well as the DNA (RNA) encoding such polypeptides, are disclosed. Also disclosed are methods for utilizing such polypeptides in diagnostic assays for identifying mutations in nucleic acid sequences encoding the polypeptides of the present invention, for detecting altered levels of the polypeptide of the present invention as a means of detecting diseases and methods of screening potential modulators, especially inhibitors, of the novel PDE4Ds (denoted PDE4D6) disclosed herein as a means of increasing cyclic AMP in neurons and thus treating neurological problems, such as long term memory loss, if not preventing such maladies entirely. Transgenic animals expressing polypeptides disclosed herein are also described.